- Disease: Acute COVID-19
- Study type: Observational Cohort Study, Treatment
- Study type descriptors: Prospective, Multicentre
- Objective: To assess the impact of monoclonal antibodies and direct antiviral therapies on clinical and virological outcomes in high-risk patients with early mild-to-moderate COVID-19, including sequencing to identify viral population changes and emerging minority variants.
- Number of participants enrolled: 735
- Study enrolling from to
- Study includes follow-up for 3 months
Sites (32)
- Centre Hospitalier Régional de Metz-Thionville (Ars-Laquenexy, France)
- Hôpital Cochin (Paris, France)
- Bicêtre Hospital (Le Kremlin-Bicêtre, France)
- Pitié-Salpêtrière Hospital (Paris, France)
- Hôpital Saint-Louis (Paris, France)
- Centre Hospitalier Universitaire d’Angers (Angers, France)
- Lariboisière Hospital (Paris, France)
- Centre Hospitalier Universitaire de Limoges (Limoges, France)
- Centre Hospitalier Universitaire de Tours (Tours, France)
- Rennes University Hospital (Rennes, France)
- Hospices Civils de Lyon (Lyon, France)
- Hôpital Avicenne (Bobigny, France)
- Tenon Hospital (Paris, France)
- Hôpital Gabriel-Montpied (Clermont-Ferrand, France)
- Centre Hospitalier Universitaire de Martinique (Fort-de-France, France)
- Centre Hospitalier Universitaire de Poitiers (Poitiers, France)
- Centre Hospitalier Régional et Universitaire de Nancy (Nancy, France)
- Centre Hospitalier Sud Francilien (Corbeil Essonnes, France)
- CHU de Nantes (Nantes, France)
- URCI – CHU de Nîmes Hôpital Carémeau (Nimes, France)
- Centre Hospitalier Agen – Nérac (Agen, France)
- CHI Poissy-Saint-Germain-en-Laye (Saint-Germain-en-Laye, France)
- CHU Dijon Bourgogne (Dijon, France)
- University Hospital of Bordeaux (Bordeaux, France)
- Centre Hospitalier – Tarbes-Lourdes (Tarbes, France)
- Hôpital Bichat-Claude-Bernard (Paris, France)
- University Hospital of Montpellier (Montpellier, France)
- Centre Hospitalier Universitaire de Toulouse (Toulouse, France)
- Centre Hospitalier Intercommunal de Poissy (Saint-Germain-en-Laye, France)
- Centre Hospitalier de Tourcoing (Tourcoing, France)
- Hôpital Necker-Enfants Malades (Paris, France)
- Saint Antoine Hospital (Paris, France)
Study Data
- Adults (18-64 years)
- Elderly (≥65 years)
- Fragile population
- Immunocompromised host
- Hospital
- Outpatient clinic
- SARS-CoV-2
- Acute COVID-19
- Pharmacological intervention
- Monoclonal antibodies
- Sotrovimab
- Tixagevimab/Cilgavimab
- Casirivimab/Imdevimab
External Links
- ClinicalTrials: https://clinicaltrials.gov/study/NCT04885452
- PubMed: https://pubmed.ncbi.nlm.nih.gov/41497402
- PubMed: https://pubmed.ncbi.nlm.nih.gov/37837962
- PubMed: https://pubmed.ncbi.nlm.nih.gov/37996072
- PubMed: https://pubmed.ncbi.nlm.nih.gov/36586513
- PubMed: https://pubmed.ncbi.nlm.nih.gov/35803386
- PubMed: https://pubmed.ncbi.nlm.nih.gov/35398409
Other information
Funders/Sponsors:
- French Ministry of Health Prevention
- French Ministry of Higher Education, Research and Innovation
The information was provided with the aid of the study investigators
If you would like to contact the Principal Investigator of the study please email: ccb@ateneo.univr.it
The data is updated up to